Open AccessPreoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists
Author(s) -
Rob van der Pas,
Richard A. Feelders,
Federico Gatto,
Christiaan de Bruin,
Alberto M. Pereira,
P. M. van Koetsveld,
D M Sprij-Mooij,
A. M. Waaijers,
Fatma Sarı Doğan,
Stefan Schulz,
Johan M. Kros,
S.W.J. Lamberts,
Leo J. Hofland
Publication year - 2013
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2013-1987
Subject(s) - pasireotide , medicine , endocrinology , cabergoline , somatostatin receptor , somatostatin , corticotropic cell , cushing's disease , dopamine receptor d2 , adenoma , acromegaly , octreotide , adrenocorticotropic hormone , dopamine , pituitary gland , hormone , prolactin , disease , growth hormone
Corticotroph pituitary adenomas often highly express the dopamine 2 receptor (D₂R) and somatostatin receptor subtype 5 (sst₅). The sst₂ expression is relatively low, likely resulting from downregulating effects of high cortisol levels. This may explain why the sst₂-preferring somatostatin analog octreotide, compared with the multi-receptor-targeting somatostatin analog pasireotide, is generally ineffective in Cushing's disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom